Professor of Urology & Surgery Urologic Oncology and Robotics American University of Beirut-MED Adjunct Professor of Urology University of Massachusetts
🧬 Can urine EV glycan signatures help us distinguish aggressive prostate cancer from indolent disease BEFORE committing patients to biopsy?
lnkd.in/exDkkJ4d
Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer
Could urine extracellular vesicle (EV) glycan profiling improve #ProstateCancer detection beyond PSA?
➡️ In this study of 135 men, Glycoflow analysis of post-DRE urine EVs improved discrimination of clinically significant prostate cancer (AUC 0.80 vs 0.71–0.72) and very significant disease (0.81–0.82 vs 0.72–0.73) when combined with clinical parameters.
✅ EV glycan profiling provided complementary diagnostic information, potentially improving biopsy decisions and reducing overdiagnosis, pending larger validation.
@sim1garz8@OncoAlert 🚨 #LPCCC27@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists
Great wrap up Dr. @nataliagandur , definitely highlights how comprehensive genomic profiling is evolving beyond identifying therapeutic targets—it's becoming a powerful tool for risk stratification and personalized prognosis.
🧬 Are we underestimating rare prostate cancer histologies simply because we rarely look for them?
nature.com/articles/s41585-0…
Rare prostate cancer histologies: detection, characteristics and treatment
Rare #ProstateCancer histologies comprise less than 5% of cases but represent a clinically important and under-recognized group.
➡️These subtypes often show aggressive behaviour, atypical metastatic patterns and poorer outcomes, while remaining underrepresented in guidelines and trials.
➡️Accurate diagnosis increasingly depends on multiparametric MRI, immunohistochemistry and genomic profiling.
➡️Molecular alterations such as DNA🧬 repair defects, TP53/RB1 loss and mismatch repair deficiency may offer therapeutic opportunities, highlighting the need for subtype-specific evidence and prospective studies.
@bavilima , @UrogerliMD, @katcollmd, @neerajaiims, @PGrivasMDPhD, @Albert0Briganti, @AndreaNecchi, @LiangChengMD, @SpiessPhilippe@Oncoalert 🚨 #LPCCC27@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists
Should high-risk prostate cancer go straight to surgery? PROTEUS finally offers a head-to-head answer: preoperative apalutamide + ADT vs prostatectomy alone 👇
cslide.ctimeetingtech.com/es…
LBA53 - Perioperative apalutamide (APA) plus androgen-deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): PROTEUS substudy
PROTEUS’s prespecified open-label substudy randomized 408 patients with high-risk localized or locally advanced #ProstateCancer 1:3 to perioperative apalutamide plus ADT or immediate radical prostatectomy plus lymphadenectomy alone.
➡️Apalutamide plus ADT significantly improved event-free survival (median not reached vs 19.1 months; HR 0.38) and MFS (HR 0.49), and reduced the need for subsequent therapy at 3 years (35% vs 68%). Grade 3/4 adverse events were higher with apalutamide (30.7% vs 21.7%).
@Albert0Briganti, @EfstathiouEleni, @ProfHadaschik, @adamkibel_uro, @delataillealex, @marty_gleave@OncoAlert 🚨 #LPCCC27@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists